Bristol-Myers Squibb vs Meta: Founders, CEOs and History

Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Meta was founded in 2004 by Mark Zuckerberg, Eduardo Saverin, Andrew McCollum and is led by Mark Zuckerberg.

Company facts

Bristol-Myers Squibb

Founded: 1887
Headquarters: Princeton, New Jersey
Current CEO: Christopher Boerner
Employees: 32,500

Founders

Bristol-Myers Squibb

Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.

Bristol-Myers Squibb founders in full

CEOs and their tenures

Bristol-Myers Squibb

Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source
Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source
James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source
Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source
Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source
Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source

Bristol-Myers Squibb CEO history in full

Timeline: Bristol-Myers Squibb and Meta side by side

1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2004Meta
Facebook launches at Harvard
Facebook launched on February 4, 2004, as a real-name student network. The product mattered because it made identity, campus trust and friend connections the core of the service before the company became a public social platform.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2007Meta
Ad platform becomes the business model
Facebook's advertising products turned user attention into a scalable commercial system. The shift mattered because the company could keep the consumer product free while charging marketers for measurable reach, targeting and conversion tools.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2012Meta
Instagram acquisition
Facebook agreed to acquire Instagram for about $1 billion in cash and stock. The deal mattered because Instagram was mobile-native at a moment when Facebook needed to prove it could survive the smartphone shift.
2012Meta
Facebook IPO
Facebook completed its initial public offering in May 2012, raising about $16 billion.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2014Meta
WhatsApp acquisition
Facebook announced a deal to acquire WhatsApp, adding a large private messaging network to a company still known mainly for public feeds.
2014Meta
Oculus acquisition
Facebook agreed to acquire Oculus VR for about $2 billion. The deal mattered because it gave the company a hardware and immersive-computing bet years before the Meta rebrand.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2021Meta
Facebook becomes Meta
Facebook changed its corporate name to Meta in 2021 to bring its apps and technologies under a new company brand.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Meta
Threads launch
Meta launched Threads in July 2023 and said the app passed 100 million sign-ups in its first five days. The launch mattered because Instagram distribution gave Meta a fast entry into real-time text conversation.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2024Meta
$164.501B revenue
Meta reported $164.501 billion in FY2024 revenue and $62.360 billion in net income. The year mattered because AI-powered ad tools, Reels monetization and expense discipline restored confidence after the 2022 slowdown.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Meta
$200.966B Revenue
Meta reported $200.966B in FY2025 revenue, $60.458B in net income, $83.276B in income from operations, and 78,865 employees at year-end.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Meta
Q2 2026 revenue up 28%
Meta reported Q2 2026 revenue of $60.80B, up 28%, and net income of $15.85B, down 14%, after $2.40B of legal charges and $1.18B of severance from a May 2026 headcount reduction. It narrowed 2026 capex guidance to $130-145B.

Acquisitions

Bristol-Myers Squibb

Orbital Therapeutics2025$1.5B
Mirati Therapeutics2024$4.8B
RayzeBio2024$4.1B
Karuna Therapeutics2024$14B
Turning Point Therapeutics2022$4.1B
MyoKardia2020$13.1B

All Bristol-Myers Squibb acquisitions

Questions about Bristol-Myers Squibb vs Meta

Who is the CEO of Bristol-Myers Squibb Company and Meta Platforms, Inc.?

Bristol-Myers Squibb Company is led by Christopher Boerner and Meta Platforms, Inc. is led by Mark Zuckerberg. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was Bristol-Myers Squibb Company founded vs Meta Platforms, Inc.?

Bristol-Myers Squibb Company was founded in 1887 — 117 years before Meta Platforms, Inc., which was founded in 2004. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Meta Platforms, Inc..

How many employees does Bristol-Myers Squibb Company have compared to Meta Platforms, Inc.?

Bristol-Myers Squibb Company employs approximately 32,500 people, while Meta Platforms, Inc. employs approximately 75,472. Meta Platforms, Inc. has the larger workforce at 75,472 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are Bristol-Myers Squibb Company and Meta Platforms, Inc. headquartered?

Both Bristol-Myers Squibb Company and Meta Platforms, Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.

Who founded Bristol-Myers Squibb Company and Meta Platforms, Inc.?

Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Meta Platforms, Inc. was founded by Mark Zuckerberg, Eduardo Saverin, Andrew McCollum, Dustin Moskovitz, Chris Hughes.

Which company has a longer operating history — Bristol-Myers Squibb Company or Meta Platforms, Inc.?

Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Meta Platforms, Inc. has been in operation for around 22 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Meta overview